Table 4.
Recently approved clinical trials using combinations of radiotherapy, PARP inhibitors, and immunotherapy.
| Treatments | Cancer | Phase | Estimated completion dates | Identifier |
|---|---|---|---|---|
| Durvalumab, Olaparib, RT | Pancreatic cancer | I | Primary and final: 31 March 2024 | NCT05411094 |
| Niraparib, Dostarlimab, RT | Rectal cancers | I/II | Primary: 31 December 2024 Final: 31 December 2026 |
NCT04926324 |
| Niraparib, Dostarlimab, RT | Pancreatic cancer | II | Primary: 19 January 2022 Final: October 2026 |
NCT04409002 |
| Niraparib, Dostarlimab, RT | Breast cancer | II | Primary: 1 April 2023 Final: 1 December 2029 |
NCT04837209 |
| Durvalumab, Tremelimumab, Olaparib, RT | SCLC | I | Primary and final: 1 June 2023 | NCT03923270 |
| Pembrolizumab, Olaparib, RT | Breast cancer | II | Primary and final: January 2025 | NCT04683679 |
| Pembrolizumab, Olaparib, ADT, RT | Prostate cancer | II | Primary: 2 January 2025 Final: 2 January 2028 |
NCT05568550 |
| Carboplatin, Durvalumab, Etoposide, Olaparib, RT | SCLC | I/II | Primary and final: 31 January 2024 | NCT04728230 |
| Pembrolizumab, Olaparib, RT | Gastric cancers | II | Primary: December 2025 Final: December 2028 |
NCT05379972 |
| Pembrolizumab, Olaparib, Etoposide, Platinum, RT, PCI | SCLC | III | Primary and final: 28 October 2027 | NCT04624204 |
| Pembrolizumab, Olaparib, Cisplatin, RT | HNSCCs | II | Primary: 31 October 2024 Final: 31 October 2025 |
NCT05366166 |
| Pembrolizumab, Olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, RT, Durvalumab | NSCLC | III | Primary and final: 6 July 2026 | NCT04380636 |
ADT, androgen deprivation therapy; HNSCCs, head and neck squamous cell carcinoma; SCLC, small-cell lung cancer; PCI, prophylactic cranial irradiation; NSCLC, non-small-cell lung cancer.